New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
14:21 EDTACTActavis price target raised to $198 from $180 at Argus
Argus increased its price target on Actavis after raising its 2013 adjusted EPS estimate above the company's guidance. The firm is upbeat about the outlook for generic drug companies in general, and predicts that Actavis will deliver mid-teens organic earnings growth in the near-term. It keeps a Buy rating on the stock.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACT

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use